OncoMatch/Clinical Trials/SSGJ-707
SSGJ-707 (PF-4404) Clinical Trials
SSGJ-707 (PF-4404) is a recombinant humanized IgG4 bispecific antibody targeting both PD-1 and VEGF, designed to combine checkpoint blockade with tumor vascular disruption in a single agent. Phase 2 monotherapy data in first-line PD-L1–positive NSCLC demonstrated promising efficacy, prompting a Phase 3 global development program with US sites led by Pfizer, which completed an exclusive ex-China licensing agreement with 3SBio in 2025. Trials also evaluate SSGJ-707 in combination with chemotherapy in colorectal cancer and in gynecologic malignancies. Eligibility typically specifies PD-L1 expression thresholds and, for combination arms, prior therapy status.
Check eligibility by cancer type
Recruiting SSGJ-707 trials
Ranked by phase and US site count.
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Pfizer
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
How OncoMatch helps you find SSGJ-707 trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every SSGJ-707 trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.